Patients with HCC as an ideal study population to assess immune checkpoint inhibitors in hepatitis B

Guanglin Xiao1, Hong Ren1

  • 1Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.

Journal of Hepatology
|October 18, 2024
PubMed
Abstract

No abstract available in PubMed .